Meiling Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Meiling Jin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Azza Abdelkarim
Safety Evaluation and Risk Management, GSK, Warsaw, Poland
1 shared publication- Cui Xiong
R&D, GSK, Shanghai, China
1 shared publication Danrong Yang
Shanghai 6th People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication- Haoyan Wang
Department of Respiratory Medicine, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, People’s Republic of China
1 shared publication - Huanying Wan
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
1 shared publication - Jian Kang
Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang, China
1 shared publication
Latest Publications
- Open Access
- 8 February 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.
- 8 February 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Open AccessEfficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.
- Open Access
- 1 January 2019
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 11 (4) , 519-528
Add-on Tiotropium in Chinese Patients With Moderate Asthma: A Pooled Subgroup Analysis of MezzoTinA-Asthma 1 and 2
Purpose: Asthma affects approximately 30 million patients in China; however, tiotropium data for Chinese patients is limited. This study aimed to assess the efficacy and safety of tiotropium in Chinese patients with moderate symptomatic asthma. Methods: A post hoc subgroup analysis was conducted on 430 Chinese patients pooled from two 24-week, replicate phase 3 trials (NCT01172808 and NCT01172821), in which they received once-daily tiotropium 2.5 mu g (Tio R2.5) or 5 mu g (Tio R5) (n = 106 or 109, respectively), twice-daily salmeterol 50 mu g (Sal 50) (n = 110), or placebo (n = 105), while maintaining inhaled corticosteroids (ICS). The co-primary endpoints assessed in week 24 were forced expiratory volume in 1 second (FEV1) peak(0-3h), response, trough FEV1 response, and responder rate as assessed using the Asthma Control Questionnaire (ACQ). Results: For both FEV1 peak(0-)(3h) responses and trough FEV1 responses, the mean treatment differences were greater for Tio R2.5, no R5, and Sal 50 compared with placebo at 0.249 L, 0.234 L, and 0.284 L, and 0.172 L, 0.180 L, and 0.164 L, respectively (P< 0.001). The ACQ responder rate in placebo, Tio R2.5, Tio R5, and Sal 50 was 58.7%, 62.3%, 59.3%, and 69.1%, respectively. Furthermore, 11 (2.6%) of 430 patients had serious adverse events (Tio R5, n = 4; Tio R2.5, n = 1; Sal 50, n = 1; and placebo, n = 5). Conclusions: Once-daily tiotropium, as add-on to medium-dose ICS, was effective and well tolerated for Chinese patients with moderate symptomatic asthma, consistent with the main analysis.
- 1 January 2019
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 11 (4) , 519-528
Open AccessAdd-on Tiotropium in Chinese Patients With Moderate Asthma: A Pooled Subgroup Analysis of MezzoTinA-Asthma 1 and 2
Purpose: Asthma affects approximately 30 million patients in China; however, tiotropium data for Chinese patients is limited. This study aimed to assess the efficacy and safety of tiotropium in Chinese patients with moderate symptomatic asthma. Methods: A post hoc subgroup analysis was conducted on 430 Chinese patients pooled from two 24-week, replicate phase 3 trials (NCT01172808 and NCT01172821), in which they received once-daily tiotropium 2.5 mu g (Tio R2.5) or 5 mu g (Tio R5) (n = 106 or 109, respectively), twice-daily salmeterol 50 mu g (Sal 50) (n = 110), or placebo (n = 105), while maintaining inhaled corticosteroids (ICS). The co-primary endpoints assessed in week 24 were forced expiratory volume in 1 second (FEV1) peak(0-3h), response, trough FEV1 response, and responder rate as assessed using the Asthma Control Questionnaire (ACQ). Results: For both FEV1 peak(0-)(3h) responses and trough FEV1 responses, the mean treatment differences were greater for Tio R2.5, no R5, and Sal 50 compared with placebo at 0.249 L, 0.234 L, and 0.284 L, and 0.172 L, 0.180 L, and 0.164 L, respectively (P< 0.001). The ACQ responder rate in placebo, Tio R2.5, Tio R5, and Sal 50 was 58.7%, 62.3%, 59.3%, and 69.1%, respectively. Furthermore, 11 (2.6%) of 430 patients had serious adverse events (Tio R5, n = 4; Tio R2.5, n = 1; Sal 50, n = 1; and placebo, n = 5). Conclusions: Once-daily tiotropium, as add-on to medium-dose ICS, was effective and well tolerated for Chinese patients with moderate symptomatic asthma, consistent with the main analysis.
- Open Access
- 11 September 2009
- Published by Bentham Science Publishers Ltd. in Journal of Epithelial Biology & Pharmacology
- Vol. 2 (1) , 44-50
Role of Airway Epithelial Cells in Development of Chronic Obstructive Pulmonary Disease
- 11 September 2009
- Published by Bentham Science Publishers Ltd. in Journal of Epithelial Biology & Pharmacology
- Vol. 2 (1) , 44-50
Open AccessRole of Airway Epithelial Cells in Development of Chronic Obstructive Pulmonary Disease